Tiger Global Management

Tiger Global Management is a New York-based investment firm that operates one of the largest crossover platforms in the world, combining a substantial public equity hedge fund with a multi-billion-dollar venture and growth investing arm that has been one of the most active capital deployers in technology and healthcare since 2010. Founded by Chase Coleman in 2001 as an offshoot of Tiger Management, the firm became famous in venture for its high-velocity, low-friction approach during the 2020-2021 cycle, when it deployed tens of billions across late-stage technology and healthcare companies. After meaningful pullback during the 2022-2023 correction, Tiger Global has retrenched into a more selective stance and now focuses its venture activity on the highest-conviction late-stage and growth bets, while still maintaining its substantial private and public crossover capacity.

The firm’s healthcare investments are concentrated in digital health, healthtech, and tech-enabled care delivery rather than biopharma or medtech. During the firm’s peak deployment years, Tiger Global invested over $1 billion across digital health companies including Komodo Health, DispatchHealth, Cityblock Health, Innovaccer, TytoCare, and Hinge Health, where Tiger and Coatue led a $600 million Series E that valued the company at $6.2 billion. The firm has historically been less active in early-stage venture and almost never leads seed or Series A rounds; its strength is large checks at Series C, D, and E, and at growth and pre-IPO crossover. Healthcare represents approximately 6 percent of the broader Tiger Global portfolio.

The firm’s senior investment partners have rotated over time, with Chase Coleman as founder and managing partner and Scott Shleifer as a long-tenured partner who anchored the venture and growth franchise during its peak years (Shleifer departed from full-time venture activity in 2023). The current senior bench includes a mix of partners and principals across the New York and other offices. Tiger Global runs unusually thin operations relative to peers; the firm has historically prized speed, low-touch board engagement, and concentrated exposure to category leaders rather than building out heavy operating-partner infrastructure.

Check sizes at venture are typically $25 million to $250 million plus at Series C, D, and E, with the capacity to anchor crossover and pre-IPO rounds with $100 million to $500 million plus checks. The firm leads and co-leads at growth and is comfortable participating in syndicates with peer crossover firms including Coatue, General Atlantic, Insight Partners, and the public-equity adjacent funds. Geographic scope is global with strong US, India, China (historically), Latin America, and Europe practices.

Founders who should approach Tiger Global are scaling digital health and healthtech operators with $50 million plus in revenue, clear category leadership, and a credible path to IPO or strategic exit within three to five years. The firm is well suited for founders who want a non-board-driven growth investor with significant capacity to anchor multiple late-stage rounds and who appreciate Tiger’s hands-off operating posture. Founders at seed or Series A, biopharma founders, devices founders, and founders building businesses without clear category-leadership trajectories should pitch other firms. Tiger Global is also a poor fit for founders who want a deeply engaged board partner; the firm’s value-add is capital, brand, and crossover-market connectivity rather than operating support.

Entry path runs through investment bankers, growth-stage venture partners at peer firms, and warm introductions from portfolio CEOs and senior healthcare operators. Tiger Global is at HLTH, JPMorgan Healthcare, and the major public-market healthcare conferences but maintains a relatively low public profile relative to peers. Cold inbound is rare and converts at very low rates; the firm largely sources through its existing networks and its public equity research bench. Diligence runs at high speed when the firm has conviction, sometimes two to four weeks from first meeting to term sheet for late-stage deals, but is rigorous on commercial metrics and category dynamics.

In a pitch, lead with the commercial proof and the category dynamics. Tiger Global partners are pattern-matchers focused on category-defining companies, ARR growth rate, gross margin, net revenue retention, and the path from current scale to IPO. They will not be impressed by macro slides or unproven theses. They want to see that you have built a real business, that you are clearly the leader in your category, and that the public-market or strategic-exit narrative is credible. The firm’s added value is most powerful as a brand-name growth investor with substantial capacity for follow-on. Founders building category-defining digital health companies who want a high-velocity growth partner with crossover capability will find Tiger Global one of the most powerful and capital-rich tier-one growth investors, with the caveat that the partnership posture is intentionally lighter-touch than most operating-driven peers.